Prolight Diagnostics
Henrik Ljung has extensive experience in financial leadership roles across various companies. Since August 2008, Henrik has served as the Owner of Ljung & Winbladh AB, taking on responsibilities as Interim CFO, Financial Manager, and overseeing special investigations and M&A projects. Current roles include Group CFO at Prolight Diagnostics, CFO at NanoEcho AB, CFO at Carbiotix, CFO at SpectraCure AB, and CFO at Lumito AB, all of which began between 2018 and 2022. Previous positions include CFO at Qlife, Acconeer AB, BGA Invest AB, and Cerdo Bankpartner AB from 2015 to 2020. Henrik Ljung holds degrees from Lund University and the Stockholm School of Economics, where studies were completed between 1980 and 2004.
This person is not in any teams
This person is not in any offices
Prolight Diagnostics
1 followers
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction. The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.